Le Lézard
Classified in: Health
Subject: RCL

Sunscope Recalls NÜTRL-Branded Tumbler Cup in Canada


TORONTO, May 23, 2024 /CNW/ - UPDATED 5/23 - NÜTRL Canada has been informed that Sunscope initiated a voluntary recall in Canada of a promotional tumbler cup due to a manufacturing defect that may present a safety hazard. This NÜTRL-branded tumbler, manufactured by Sunscope, was offered as a gift with purchase in select stores in Canada in April and May of 2024.  

Based on their testing to date, Sunscope has determined that some of the tumblers may contain a chemical cleaning solution that was trapped between the inner walls of the tumbler, which contains some levels of sulfuric and phosphoric acids. This solution may release when the tumbler is filled with liquid, posing a potential risk of serious injury. The interaction between the solution and the tumbler may also result in elevated levels of iron, chromium and nickel. A range of health effects has been associated with ingestion of these substances, including burning of the lips, tongue, throat, stomach, and other tissue damage, and nausea, vomiting, stomach cramps and diarrhea. Health effects associated with skin contact with these substances include blistering, burns, pain, and redness.  

Consumers should immediately stop using the recalled tumbler and call this toll-free number for further information: 1 (866) 846-1778; or email [email protected]. If you are experiencing any symptoms, you should seek medical attention. Visit the Canadian Centre for Occupational Health & Safety website for more information on sulfuric and phosphoric acid and potential symptoms of exposure: www.ccohs.ca/oshanswers/chemicals/chem_profiles.  

Consumer safety is our top priority. Together with Sunscope and their distributor Staples Promotional Products Canada, we are working with Health Canada to proactively notify consumers.  

SOURCE NÜTRL Canada


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: